Medical device maker B. Braun Melsungen is appealing a ruling that invalidated its intravenous catheter patents and dismissed allegations of infringement against rival Becton Dickinson.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
A showdown between global pharmaceutical giants over the world’s best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer’s Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.
Generic drug maker Sandoz has been found liable for patent infringement and misleading and deceptive conduct in a case by pharmaceutical giant Lundbeck over its blockbuster antidepressant Lexapro, ending a battle that has raged for 15 years.
Surgical mesh devices, including the controversial urogynaecological mesh devices that are at the centre of two high-stakes class actions, will soon face a higher bar for regulatory approval.
GlaxoSmithKline has won approval for a patent for a vaccine to prevent a common respiratory virus affecting infants, beating out a challenge from a rival that has developed a competing vaccine.
Consumer goods giant Reckitt Benckiser is seeking more information after advertisements for rival AFT Pharmaceuticals’ Maxigesic painkiller were found in-store and online despite the court ordering the removal of the misleading displays earlier this month.
A court has delivered a loss for Germany-based B. Braun Melsungen, dismissing its allegations that US-based device manufacturer Becton Dickinson infringed three of its intravenous catheter patents and ruling the patents invalid.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
AFT Pharmaceuticals has been ordered to pull advertisements for its painkiller Maxigesic after the Federal Court ruled in favour of rival Reckitt Benckiser, finding the ads breached Australian Consumer Law.